NCT03659214View on ClinicalTrials.gov

Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults

CompletedOBSERVATIONAL
Enrollment

19

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

January 19, 2022

Study Completion Date

January 19, 2022

Conditions
Cystic Fibrosis
Interventions
BEHAVIORAL

Questionnaires

Answering 4 questionnaires : anxiety, depression, quality of life and adherence

Trial Locations (1)

75015

Department of Pneumology -CRCM - Necker - Enfants maladies Hospital (AP-HP), Paris

All Listed Sponsors
collaborator

VERTEX Pharmaceutical

UNKNOWN

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03659214 - Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults | Biotech Hunter | Biotech Hunter